Rare Disease Expertise On FDA Advisory Committees Gains Capitol Hill Attention

 
• By Derrick Gingery

With Congress watching whether enough experts are on advisory committees for orphan drugs, the US FDA may be pressured into changes.

Expert stamp
The FDA is streamlining advisory committee member recruitment and retention and developing other process improvements. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers